Free Trial
NASDAQ:APGE

Apogee Therapeutics (APGE) Stock Price, News & Analysis

Apogee Therapeutics logo
$37.41 +1.01 (+2.78%)
As of 11:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Apogee Therapeutics Stock (NASDAQ:APGE)

Key Stats

Today's Range
$35.75
$37.27
50-Day Range
$28.79
$40.84
52-Week Range
$26.20
$63.50
Volume
49,509 shs
Average Volume
638,478 shs
Market Capitalization
$1.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$94.60
Consensus Rating
Buy

Company Overview

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Apogee Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

APGE MarketRank™: 

Apogee Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 665th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Apogee Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Apogee Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Apogee Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Apogee Therapeutics are expected to decrease in the coming year, from ($3.09) to ($3.67) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Apogee Therapeutics is -15.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Apogee Therapeutics is -15.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Apogee Therapeutics has a P/B Ratio of 4.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Apogee Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    27.37% of the float of Apogee Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Apogee Therapeutics has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Apogee Therapeutics has recently decreased by 1.64%, indicating that investor sentiment is improving.
  • Dividend Yield

    Apogee Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Apogee Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    27.37% of the float of Apogee Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Apogee Therapeutics has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Apogee Therapeutics has recently decreased by 1.64%, indicating that investor sentiment is improving.
  • News Sentiment

    Apogee Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Apogee Therapeutics this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Apogee Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $587,191.00 in company stock.

  • Percentage Held by Insiders

    42.77% of the stock of Apogee Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Apogee Therapeutics' insider trading history.
Receive APGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APGE Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

APGE Stock Analysis - Frequently Asked Questions

Apogee Therapeutics' stock was trading at $45.30 at the beginning of 2025. Since then, APGE stock has decreased by 19.6% and is now trading at $36.40.
View the best growth stocks for 2025 here
.

Apogee Therapeutics, Inc. (NASDAQ:APGE) announced its earnings results on Monday, May, 12th. The company reported ($0.95) EPS for the quarter, beating analysts' consensus estimates of ($1.19) by $0.24.

Apogee Therapeutics (APGE) raised $282 million in an initial public offering (IPO) on Friday, July 14th 2023. The company issued 17,650,000 shares at a price of $15.00-$17.00 per share.

Apogee Therapeutics' top institutional shareholders include Octagon Capital Advisors LP (23.84%), Wellington Management Group LLP (12.22%), Driehaus Capital Management LLC (5.21%) and Vanguard Group Inc. (4.64%). Insiders that own company stock include Nimish P Shah, Michael Thomas Henderson, Carl Dambkowski, Jane Henderson and Mark C Mckenna.
View institutional ownership trends
.

Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Apogee Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Netflix (NFLX) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
5/12/2025
Today
5/29/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:APGE
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$94.60
High Stock Price Target
$110.00
Low Stock Price Target
$89.00
Potential Upside/Downside
+159.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$83.99 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$7.50 per share
Price / Book
4.85

Miscellaneous

Free Float
28,772,000
Market Cap
$1.68 billion
Optionable
Optionable
Beta
1.70
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:APGE) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners